Abstract：
BACKGROUND: Terbinafine has been successfully used in the treatment of human sporotrichosis; however, its effectiveness in the treatment of feline sporotrichosis is unknown. Therefore, this study aimed to describe the use of terbinafine in the treatment of feline sporotrichosis.
METHODS: A cohort study was conducted in cats with sporotrichosis to assess the effectiveness and safety of terbinafine (30‒60 mg/kg/day). Clinical examination and analysis of laboratory parameters were performed monthly until clinical signs resolved or terbinafine treatment was discontinued.
RESULTS: Of the 54 cats with sporotrichosis included in the study, 19 were lost during follow-up and five were withdrawn from the study due to switching to treatment with another prescription drug. Of the remaining 30 cats, 10 achieved clinical cure, with a median treatment time of 18.5 weeks. Treatment failed in 18 cases, and two cats died. Twenty-two cats had adverse reactions to terbinafine treatment, and 10 cats showed elevation of serum transaminases.
CONCLUSIONS: Loss during follow-up was high, which makes it difficult to draw accurate conclusions regarding clinical outcomes.
CONCLUSIONS: The low rate of clinical cure observed suggests that terbinafine does not represent an effective treatment option for cases of feline sporotrichosis.
METHODS: A cohort study was conducted in cats with sporotrichosis to assess the effectiveness and safety of terbinafine (30‒60 mg/kg/day). Clinical examination and analysis of laboratory parameters were performed monthly until clinical signs resolved or terbinafine treatment was discontinued.
RESULTS: Of the 54 cats with sporotrichosis included in the study, 19 were lost during follow-up and five were withdrawn from the study due to switching to treatment with another prescription drug. Of the remaining 30 cats, 10 achieved clinical cure, with a median treatment time of 18.5 weeks. Treatment failed in 18 cases, and two cats died. Twenty-two cats had adverse reactions to terbinafine treatment, and 10 cats showed elevation of serum transaminases.
CONCLUSIONS: Loss during follow-up was high, which makes it difficult to draw accurate conclusions regarding clinical outcomes.
CONCLUSIONS: The low rate of clinical cure observed suggests that terbinafine does not represent an effective treatment option for cases of feline sporotrichosis.
摘要：
背景：特比萘芬已成功用于治疗人孢子丝菌病；然而，其在治疗猫孢子丝菌病中的有效性尚不清楚。因此,本研究旨在描述特比萘芬在治疗猫孢子丝菌病中的应用。
方法：在孢子丝菌病的猫中进行了一项队列研究，以评估特比萘芬（30〜60mg/kg/天）的有效性和安全性。每月进行临床检查和实验室参数分析，直到临床症状消退或停用特比萘芬治疗。
结果：在研究中纳入的54只孢子丝菌病猫中，19人在随访期间丢失，5人由于改用另一种处方药治疗而退出研究。剩下的30只猫,10取得临床治愈,中位治疗时间为18.5周。18例治疗失败，两只猫死了.二十二只猫对特比萘芬治疗有不良反应，和10只猫显示血清转氨酶升高。
结论：随访期间的损失很高，这使得很难得出关于临床结果的准确结论。
结论：观察到的临床治愈率低表明特比萘芬不是猫科动物孢子丝菌病病例的有效治疗选择。
方法：在孢子丝菌病的猫中进行了一项队列研究，以评估特比萘芬（30〜60mg/kg/天）的有效性和安全性。每月进行临床检查和实验室参数分析，直到临床症状消退或停用特比萘芬治疗。
结果：在研究中纳入的54只孢子丝菌病猫中，19人在随访期间丢失，5人由于改用另一种处方药治疗而退出研究。剩下的30只猫,10取得临床治愈,中位治疗时间为18.5周。18例治疗失败，两只猫死了.二十二只猫对特比萘芬治疗有不良反应，和10只猫显示血清转氨酶升高。
结论：随访期间的损失很高，这使得很难得出关于临床结果的准确结论。
结论：观察到的临床治愈率低表明特比萘芬不是猫科动物孢子丝菌病病例的有效治疗选择。
